The Receptor Interacting Serine/Threonine Protein Kinase 1 pipeline drugs market research report outlays comprehensive information on the Receptor Interacting Serine/Threonine Protein Kinase 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Receptor Interacting Serine/Threonine Protein Kinase 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Immunology, Central Nervous System, Gastrointestinal, and Respiratory which include the indications Inflammation, Rheumatoid Arthritis, Alzheimer’s Disease, Multiple Sclerosis, Ulcerative Colitis, Crohn’s Disease (Regional Enteritis), Idiopathic Pulmonary Fibrosis, and Lung Injury. It also reviews key players involved in Receptor Interacting Serine/Threonine Protein Kinase 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Receptor Interacting Serine/Threonine Protein Kinase 1 pipeline targets constitutes close to 25 molecules. Out of which, approximately 23 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 7, 4, 10, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.
Receptor Interacting Serine/Threonine Protein Kinase 1 overview
Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is a protein that regulates cell survival and death. It’s a key regulator of the cellular decision between pro-survival NF-κB signaling and death in response to inflammatory and pro-death stimuli. RIPK1 is highly expressed in gallbladder cancer, and is important in promoting tumor proliferation and invasion.
For a complete picture of Receptor Interacting Serine/Threonine Protein Kinase 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
